Atherosclerosis of Renal Artery: Causes and Treatment

Atherosclerosis of the renal artery is the leading cause of narrowed blood flow to the kidneys, responsible for the vast majority of cases of what physicians call renovascular disease. The same fatty plaque buildup that clogs coronary arteries can gradually obstruct one or both renal arteries, triggering hard-to-control high blood pressure and, over time, progressive kidney damage. Because the condition shares its root cause with coronary and peripheral artery disease, people who have it almost always carry atherosclerosis in other parts of the body as well, placing them at elevated risk of heart attack and stroke.

Who Gets It and Why

Atherosclerotic renal artery stenosis (often shortened to ARAS) develops through the same process that drives plaque formation elsewhere: cholesterol-laden deposits infiltrate the artery wall near the point where the renal artery branches off the aorta, gradually hardening and narrowing the vessel. The plaque typically forms at or near the opening of the renal artery, a location referred to as the ostium, where turbulent blood flow makes the vessel wall especially vulnerable.

The risk factors track closely with those for heart disease. A study of patients undergoing cardiac catheterization found that age, severity of coronary artery disease, congestive heart failure, female sex, and peripheral vascular disease were all independent predictors of having renal artery disease as well.¹ Interestingly, hypertension itself was not an independent predictor in that analysis, likely because high blood pressure is so common among cardiac catheterization patients that it did not separate those with renal artery disease from those without. Diabetes, smoking, and high cholesterol round out the familiar roster of contributors. People with ARAS tend to have atherosclerosis in other vascular beds, which means the renal artery problem is often discovered alongside coronary or carotid disease.²

What Happens Inside the Body When Blood Flow Drops

When plaque narrows the renal artery enough to meaningfully reduce blood flow, the kidney on that side senses the drop and responds as if the whole body’s blood pressure were too low. It ramps up release of renin, an enzyme that kicks off a hormonal chain reaction involving angiotensin and aldosterone. The net effect is body-wide: blood vessels constrict, the body holds onto more salt and water, and blood pressure climbs. This is why renal artery stenosis can cause severe hypertension that resists the usual medications.³

Beyond driving up blood pressure, the chronic reduction in blood flow starves the kidney of oxygen. Over months and years, this oxygen deprivation injures the small blood vessels and filtering units within the kidney itself. The tissue becomes scarred and fibrotic, a process that progressively erodes the kidney’s ability to filter waste. Once this damage sets in, it may be only partially reversible, even if blood flow is later restored.⁴ This downstream kidney injury, called ischemic nephropathy, is increasingly recognized as a meaningful cause of chronic kidney disease and, in severe cases, can progress to the point where dialysis is needed.⁵

How the Condition Shows Up Clinically

ARAS is sneaky. Many people have significant narrowing of one or both renal arteries without obvious symptoms, and the disease is often found incidentally during imaging for something else. When it does make itself known, the most common presentation is high blood pressure that either starts abruptly in someone over 55, gets dramatically harder to control, or requires three or more medications without reaching target levels. If your blood pressure was reasonably stable and then suddenly worsened despite consistent treatment, your doctor may suspect a renovascular cause.

A more dramatic presentation is flash pulmonary edema, where fluid floods the lungs suddenly and causes severe shortness of breath. This tends to occur in people with bilateral stenosis (narrowing on both sides) or stenosis affecting the artery to a single functioning kidney. The mechanism is straightforward: the kidneys cannot adequately excrete salt and water, volume builds up, and the heart becomes overwhelmed. Flash pulmonary edema that keeps recurring despite standard heart-failure treatment should raise a red flag for underlying renal artery stenosis.³

A third pattern is an unexplained, progressive decline in kidney function, sometimes discovered when bloodwork shows rising creatinine levels. When kidney function worsens after starting a class of blood pressure medications called ACE inhibitors or angiotensin receptor blockers, renal artery stenosis is a classic suspect. These drugs lower the pressure inside the kidney’s filtering apparatus, which is normally helpful but can be dangerous if the artery feeding that kidney is already too narrow to maintain adequate flow.

How Doctors Find and Measure the Narrowing

Diagnosing ARAS involves both confirming that a narrowing exists and figuring out whether that narrowing is actually causing harm. These are two separate questions, and the gap between them explains much of the controversy around treatment.

Duplex ultrasound is usually the first-line screening tool. It uses Doppler measurements to estimate how fast blood is moving through the renal artery. A high peak velocity suggests the blood is being forced through a tight space. One large analysis found that a peak systolic velocity above 285 cm/s provided about 81% overall accuracy for detecting at least 60% narrowing, with 90% specificity.⁶ Ultrasound is noninvasive, inexpensive, and widely available, but its accuracy depends heavily on the operator’s skill and the patient’s body habitus. In obese patients or those with bowel gas obscuring the view, results can be unreliable.

MR angiography offers detailed images without exposing the patient to radiation. However, its spatial resolution has limits, and there is meaningful variability in how different observers read the same scan. It also cannot adequately assess a stent that has already been placed, because the metal distorts the magnetic signal.⁷ CT angiography provides excellent anatomic detail but requires iodine-based contrast dye, which can itself harm kidneys that are already compromised.

Catheter-based angiography remains the gold standard for visualizing the artery, but even this has limitations. A study comparing angiographic measurements with actual pressure readings across the stenosis found that commonly used imaging criteria tend to overestimate how severe the narrowing truly is. The researchers concluded that this overdiagnosis likely explains why many patients who appear to have significant stenosis on imaging do not benefit from having a stent placed.⁸ In other words, a narrowing that looks tight on a picture may not actually be restricting blood flow enough to matter physiologically.

Medical Treatment as the Foundation

Regardless of whether a procedure to open the artery is planned, medical therapy forms the backbone of managing ARAS. This means treating the underlying atherosclerosis aggressively: controlling blood pressure, lowering cholesterol, managing diabetes, and stopping smoking. In practice, it usually involves several medications working together.

Blood pressure control typically requires multiple drugs. ACE inhibitors and angiotensin receptor blockers are particularly effective because they directly counteract the hormone surge triggered by renal artery narrowing. There is a well-known catch, though: these drugs can cause a temporary rise in creatinine, especially in patients with bilateral stenosis or stenosis to a solitary kidney. A study tracking patients who started enalapril (an ACE inhibitor) found that those who experienced a creatinine rise of at least 20% saw it fully reverse once the drug was stopped.⁹ None of those patients developed acute kidney failure requiring dialysis. The practical takeaway is that ACE inhibitors can be used carefully in ARAS patients with close monitoring of kidney function, particularly in the first few weeks.

Statins play a dual role. Beyond lowering cholesterol, they appear to slow the progression of plaque within the renal artery itself. One study found that statin therapy reduced the risk of disease progression with a relative risk of about 0.28, meaning treated patients were roughly a quarter as likely to see their stenosis worsen. A greater proportion of patients on statins even showed some regression of their narrowing.¹⁰ Separately, a randomized trial comparing intensive versus conventional lipid-lowering in patients who had received a renal artery stent showed that the intensive-treatment group had better kidney function at one year, with higher estimated filtration rates and lower urinary albumin levels.¹¹ Antiplatelet therapy, typically aspirin, is also standard given the widespread nature of the atherosclerotic disease.

Stenting and Why the Evidence Is More Complicated Than You Might Expect

For years, the intuitive approach to a blocked artery was to open it up. Balloon angioplasty and stent placement can mechanically widen the narrowed segment, restoring blood flow almost immediately. In selected patients, the technical success rate is high, and for lesions right at the opening of the artery where elastic recoil after balloon dilation is common, stents have become the standard interventional approach.

The problem is that two large randomized trials tested whether adding a stent to good medical therapy actually improved outcomes for typical ARAS patients, and neither showed a clear benefit. The CORAL trial, the larger of the two, followed patients for a median of about 43 months and found no significant difference in the combined rate of cardiovascular events, kidney failure, or death between the group that received stents plus medication and the group treated with medication alone. The composite event rate was about 35% in both groups.¹² The ASTRAL trial, published earlier, reached a similar conclusion: no benefit of revascularization on renal or cardiovascular outcomes at a median follow-up of about 34 months.¹³

These findings shifted the conversation dramatically. For the majority of patients with stable ARAS and manageable blood pressure, medical therapy alone is now the preferred strategy in most clinical guidelines. Stenting has not gone away, but its role has narrowed considerably.

When a Procedure Might Still Make Sense

The trial results do not mean stenting is never useful. Both CORAL and ASTRAL enrolled a broad mix of patients, and critics have argued that the trials may have included too many people with mild stenosis or with kidneys already too damaged to recover, diluting any benefit that might exist in a more carefully selected group. Certain clinical scenarios still push physicians toward revascularization:

Recurrent flash pulmonary edema: When fluid repeatedly backs up into the lungs despite aggressive medical therapy, restoring renal blood flow can break the cycle of salt and water retention.
Rapidly declining kidney function: If creatinine is climbing steeply and the cause appears to be worsening stenosis rather than another kidney disease, opening the artery may preserve whatever filtering capacity remains.
Failure of maximal medical therapy: Blood pressure that stays dangerously elevated despite four or five drugs at full doses sometimes responds to revascularization when medication alone cannot get the job done.
Bilateral critical stenosis: When both renal arteries are severely narrowed, the kidneys have no compensatory workaround, and the clinical situation tends to be more urgent.

The challenge is identifying, before the procedure, which patients will actually benefit. One approach uses pressure measurements taken directly across the narrowing during catheterization. Research has shown that a mean pressure gradient of 20 mm Hg or more, measured after stimulating blood flow with dopamine, is highly predictive of a blood pressure improvement after stenting.¹⁴ This kind of functional assessment goes beyond simply looking at how narrow the artery appears on a picture. It asks whether the narrowing is actually restricting flow enough to drive the patient’s symptoms.

Predicting Kidney Recovery After Revascularization

Even when blood flow is successfully restored, a kidney that has been starved for months or years may not bounce back. The degree of internal scarring matters enormously. One tool for gauging this is the resistive index, measured with ultrasound in the small arteries within the kidney itself. A high resistive index suggests that the kidney tissue downstream of the stenosis has already undergone significant structural damage. Research in patients with one-sided ARAS found that the resistive index measured in the opposite kidney was an independent predictor of whether kidney function improved after successful stenting.¹⁵ If the contralateral kidney also has a high resistive index, the problem is more systemic than focal, and the likelihood of meaningful improvement drops.

An emerging approach uses a specialized MRI technique called BOLD (blood oxygen level dependent) imaging, which measures oxygenation within the kidney tissue itself. The idea is that by mapping which parts of the kidney are most oxygen-starved, doctors could identify kidneys that are still salvageable versus those that have crossed the point of no return.¹⁶ This technology is still largely a research tool rather than a routine clinical test, but it represents the direction the field is moving: away from treating based solely on the anatomy of the narrowing and toward treating based on the biology of the kidney behind it.

How Atherosclerotic Stenosis Differs from Other Causes of Renal Artery Narrowing

Not all renal artery narrowing is atherosclerotic. The other major cause is fibromuscular dysplasia (FMD), a condition that tends to affect younger women and involves abnormal growth of the arterial wall rather than cholesterol plaque. FMD typically narrows the middle or far portion of the renal artery, producing a characteristic “string of beads” pattern on imaging, whereas atherosclerotic lesions cluster at the ostium. The distinction matters beyond appearances. Research comparing the two conditions found that renal blood flow is significantly higher in FMD than in atherosclerotic stenosis, and the pattern of renin secretion differs fundamentally. In ARAS, the affected kidney pumps out excess renin in a predictable way. In FMD, this expected pattern does not hold, and the relationship between blood pressure and renin activity is essentially the opposite of what is seen in ARAS.¹⁷

This has practical consequences. Because FMD is not a systemic disease of atherosclerosis, people who have it tend to be younger, healthier overall, and more likely to see their blood pressure normalize after the narrowing is opened. Angioplasty alone (without a stent) often works well for FMD because the arterial wall is fundamentally different from the stiff, calcified wall seen in atherosclerosis. For ARAS, the calcified plaque is more rigid and prone to recoiling after balloon dilation, which is why stents became standard for atherosclerotic lesions at or near the ostium when a procedure is performed.

Living with ARAS and the Broader Cardiovascular Picture

Because ARAS is really a local manifestation of a body-wide disease, managing it means managing cardiovascular risk comprehensively. People with ARAS face higher rates of heart attack, stroke, and cardiovascular death than the general population, and that risk persists regardless of whether the renal artery itself is stented. In the long-term follow-up of the ASTRAL trial, cardiovascular events remained the primary concern for both treatment groups.¹³ This reinforces the idea that fixating on the renal artery alone misses the larger threat.

For patients, this means that the daily work of medication adherence, blood pressure monitoring, cholesterol management, dietary changes, and exercise may matter more than any single procedure. Kidney function should be tracked regularly with blood tests, and any new symptoms like sudden shortness of breath, unexplained swelling, or worsening blood pressure control should prompt a conversation with your doctor about whether the stenosis is progressing. The condition is chronic, and for most people, the goal is not to cure the narrowing but to keep the kidneys and heart functioning as well as possible for as long as possible.

Why Overdiagnosis Remains a Real Problem

One of the more underappreciated aspects of ARAS is how often it gets overdiagnosed or over-treated. As noted in the comparison of angiography and ultrasound against direct pressure measurements, widely accepted imaging criteria tend to label stenosis as significant even when the pressure drop across the narrowing is modest.⁸ A renal artery that looks 60% narrowed on a scan may not actually be restricting enough flow to cause the patient’s symptoms. If a stent is placed based on anatomic appearance alone, the patient bears the risks of the procedure (bleeding, contrast dye exposure, cholesterol embolization) without the physiological benefit.

This mismatch between what imaging shows and what the kidney actually experiences is the central puzzle of the field. It explains why the large trials failed to show a benefit of stenting across the board: the trials enrolled patients based largely on how the artery looked, not on whether the narrowing was functionally responsible for their clinical problems. The push toward functional testing, whether through pressure gradients, resistive indices, or advanced MRI, is essentially an effort to solve this problem by asking a better question before deciding on treatment. For patients, the takeaway is worth remembering: a narrowed renal artery on an imaging study does not automatically mean you need a stent, and the conversation with your doctor should focus not just on how the artery looks but on whether it is actually causing your blood pressure or kidney issues.